GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (FRA:IQI) » Definitions » Current Ratio

Incannex Healthcare (FRA:IQI) Current Ratio : 5.70 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Incannex Healthcare Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Incannex Healthcare's current ratio for the quarter that ended in Mar. 2024 was 5.70.

Incannex Healthcare has a current ratio of 5.70. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Incannex Healthcare's Current Ratio or its related term are showing as below:

FRA:IQI' s Current Ratio Range Over the Past 10 Years
Min: 0.41   Med: 2.56   Max: 37.62
Current: 5.7

During the past 13 years, Incannex Healthcare's highest Current Ratio was 37.62. The lowest was 0.41. And the median was 2.56.

FRA:IQI's Current Ratio is ranked better than
91.33% of 1073 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs FRA:IQI: 5.70

Incannex Healthcare Current Ratio Historical Data

The historical data trend for Incannex Healthcare's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Current Ratio Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.41 3.95 12.35 18.85

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 9.02 - 6.69 5.70

Competitive Comparison of Incannex Healthcare's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Current Ratio distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Current Ratio falls into.



Incannex Healthcare Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Incannex Healthcare's Current Ratio for the fiscal year that ended in Jun. 2022 is calculated as

Current Ratio (A: Jun. 2022 )=Total Current Assets (A: Jun. 2022 )/Total Current Liabilities (A: Jun. 2022 )
=24.651/1.308
=18.85

Incannex Healthcare's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=15.013/2.635
=5.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incannex Healthcare  (FRA:IQI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Incannex Healthcare Current Ratio Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (FRA:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.